NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 01 03:42PM ET
1.57
Dollar change
-0.03
Percentage change
-2.19
%
IndexRUT P/E- EPS (ttm)-1.43 Insider Own50.49% Shs Outstand32.91M Perf Week-11.58%
Market Cap67.07M Forward P/E- EPS next Y-0.85 Insider Trans0.00% Shs Float21.22M Perf Month-14.95%
Enterprise Value92.83M PEG- EPS next Q-0.35 Inst Own16.68% Short Float12.91% Perf Quarter28.28%
Income21.12M P/S- EPS this Y58.87% Inst Trans7.56% Short Ratio4.43 Perf Half Y-7.94%
Sales0.00M P/B- EPS next Y48.95% ROA54.08% Short Interest2.74M Perf YTD-17.20%
Book/sh-0.99 P/C8.87 EPS next 5Y- ROE- 52W High9.25 -83.08% Perf Year-79.16%
Cash/sh0.18 P/FCF- EPS past 3/5Y16.44% 36.59% ROIC- 52W Low0.87 79.89% Perf 3Y-92.82%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility9.84% 7.51% Perf 5Y-94.33%
Dividend TTM- EV/Sales- EPS Y/Y TTM111.90% Oper. Margin- ATR (14)0.13 Perf 10Y-
Dividend Ex-Date- Quick Ratio0.57 Sales Y/Y TTM- Profit Margin- RSI (14)39.55 Recom1.50
Dividend Gr. 3/5Y- - Current Ratio0.72 EPS Q/Q81.25% SMA20-11.39% Beta0.26 Target Price10.00
Payout- Debt/Eq- Sales Q/Q- SMA50-6.61% Rel Volume1.03 Prev Close1.60
Employees23 LT Debt/Eq- EarningsMay 15 AMC SMA200-42.57% Avg Volume618.52K Price1.57
IPOJun 14, 2016 Option/ShortYes / Yes EPS/Sales Surpr.26.31% -100.00% Trades Volume607,041 Change-2.19%
Date Action Analyst Rating Change Price Target Change
Dec-02-24Downgrade Chardan Capital Markets Buy → Neutral
Mar-27-24Upgrade BTIG Research Neutral → Buy $50
Feb-15-24Upgrade Chardan Capital Markets Neutral → Buy $3
Jan-25-24Upgrade Guggenheim Neutral → Buy
Dec-27-23Upgrade CapitalOne Equal Weight → Overweight $5
Aug-31-23Downgrade H.C. Wainwright Buy → Neutral $5 → $1
Aug-31-23Downgrade Chardan Capital Markets Buy → Neutral
Aug-30-23Downgrade Guggenheim Buy → Neutral
Aug-30-23Downgrade CapitalOne Overweight → Equal Weight
Aug-30-23Downgrade Cantor Fitzgerald Overweight → Neutral $4.50 → $1
Today 08:05AM
Jun-18-25 09:05AM
Jun-11-25 05:06AM
Jun-10-25 08:05AM
Jun-02-25 07:00AM
06:30AM Loading…
May-23-25 06:30AM
May-22-25 04:01PM
May-15-25 04:01PM
Apr-08-25 08:45AM
Mar-20-25 05:24PM
Feb-28-25 08:05AM
Feb-19-25 09:00AM
Feb-14-25 08:05AM
Feb-04-25 09:05AM
Jan-31-25 08:05AM
09:05AM Loading…
Jan-23-25 09:05AM
Jan-22-25 09:05AM
Jan-16-25 12:09PM
06:00AM
Jan-08-25 09:15AM
Dec-30-24 07:45AM
Dec-28-24 10:50PM
08:10AM
Dec-27-24 08:05AM
Dec-13-24 04:30PM
Dec-04-24 08:05AM
Dec-03-24 04:30PM
Nov-30-24 05:50AM
Nov-27-24 11:08AM
11:07AM
09:27AM Loading…
09:27AM
06:50AM
Nov-06-24 08:05AM
Oct-17-24 09:00AM
Sep-16-24 08:05AM
Sep-13-24 09:05AM
Sep-04-24 08:35AM
Sep-03-24 08:45AM
Aug-15-24 06:20AM
Aug-14-24 07:05AM
Aug-12-24 09:05AM
Aug-09-24 07:16AM
Aug-07-24 08:35AM
Jul-30-24 09:10AM
Jul-08-24 08:35AM
Jun-25-24 07:30AM
Jun-17-24 08:00AM
Jun-12-24 10:00AM
Jun-11-24 09:05AM
Jun-10-24 08:00AM
Jun-06-24 10:30AM
May-28-24 08:05AM
May-17-24 04:27AM
May-15-24 10:53PM
05:00PM
May-13-24 11:18AM
08:50AM
May-09-24 08:45AM
May-02-24 09:05AM
Apr-29-24 09:00AM
Apr-26-24 06:37AM
Apr-15-24 04:15PM
12:54PM
Apr-10-24 03:30PM
Mar-22-24 07:35AM
Mar-18-24 05:10PM
Mar-12-24 08:05AM
Mar-06-24 03:36PM
Feb-25-24 01:37PM
Feb-14-24 05:27PM
08:05AM
Jan-31-24 08:05AM
Jan-24-24 08:06AM
Jan-23-24 08:00AM
Jan-02-24 10:18PM
Dec-27-23 02:03PM
09:30AM
Dec-26-23 02:15PM
Dec-22-23 08:05AM
Dec-19-23 08:05AM
Dec-06-23 08:05AM
Nov-27-23 08:05AM
06:30AM
Nov-15-23 02:04PM
Nov-14-23 08:05AM
Nov-09-23 08:52AM
Nov-02-23 08:05AM
Nov-01-23 08:05AM
Oct-17-23 05:22PM
Oct-11-23 05:49PM
Sep-29-23 08:05AM
Sep-21-23 08:05AM
Sep-05-23 08:05AM
Aug-31-23 10:15AM
Aug-30-23 06:11AM
06:00AM
Aug-28-23 11:47AM
Aug-14-23 09:55AM
08:05AM
Aug-01-23 08:45AM
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KENYON LAWRENCE AChief Financial OfficerSep 26 '24Buy5.695,00028,4465,946Sep 30 04:53 PM